The high-risk group was characterized by higher expression of CD163, which is a marker of M2-like tumor-associated macrophages (TAMs), and MYD88, which is a marker of NF-kappa-B activation, cytokine secretion, and inflammatory response. Here, MYD88 is linked to neoplasm.